Showing 1,241 - 1,260 results of 100,872 for search '(( 12 nn decrease ) OR ( 5 ((((non decrease) OR (point decrease))) OR (a decrease)) ))', query time: 1.05s Refine Results
  1. 1241
  2. 1242
  3. 1243

    <i>In vivo</i> treatment with entinostat decreases Foxp3 expression in Tregs and inhibits Tregs function. by Li Shen (110858)

    Published 2012
    “…Cells were harvested from spleens and lymph nodes. A, <i>In vivo</i> entinostat treatment decreased the expression level of Foxp3 in CD4<sup>+</sup>Foxp3<sup>+</sup> (Treg) cells. …”
  4. 1244
  5. 1245
  6. 1246

    Data_Sheet_1_rdHSV-CA8 non-opioid analgesic gene therapy decreases somatosensory neuronal excitability by activating Kv7 voltage-gated potassium channels.docx by Munal B. Kandel (18526539)

    Published 2024
    “…Voltage clamp recordings indicate an effect via Kv7 channels in vHCA8-infected small DRG neurons. These data demonstrate for the first time that vHCA8 produces Kv7 channel activation, which decreases neuronal excitability in nociceptors. …”
  7. 1247
  8. 1248
  9. 1249
  10. 1250
  11. 1251

    AMPK activators reverse the decreased expression of GR induced by DEX in cultured prefrontal cortical astrocytes. by Shi-Ying Yuan (2937669)

    Published 2016
    “…<p>(A) Representative western blot images (upper) and summarized data (lower) showing the effects of AICAR (n = 5 for each group) (A), ASP (n = 4 for each group) (B), and MET (n = 7 for each group) (C) on DEX-induced decreases of GR and pAMPK in cultured astrocytes. …”
  12. 1252
  13. 1253
  14. 1254
  15. 1255
  16. 1256
  17. 1257
  18. 1258

    Supplementary Material for: The Risk of Ischemic Stroke after an Acute Myocardial Infarction in Patients with Decreased Renal Function by Jakobsson S. (4146769)

    Published 2014
    “…<b><i>Conclusions:</i></b> Ischemic stroke is a more common complication after an AMI in CKD patients than in non-CKD patients, but the risk has decreased in recent years. …”
  19. 1259
  20. 1260

    Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…In the recurrence group, BCVA (logMAR) showed no significant improvement over time: 0.37 ± 0.20 preoperatively and 0.35 ± 0.23, 0.35 ± 0.18, 0.31 ± 0.23, 0.34 ± 0.26, 0.28 ± 0.30, and 0.24 ± 0.23 at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal-Wallis test, p = 0.45). In contrast, the non-recurrence group demonstrated significant and sustained improvement from 0.31 ± 0.25 preoperatively to 0.25 ± 0.25, 0.23 ± 0.26, 0.23 ± 0.28, 0.21 ± 0.27, 0.20 ± 0.30, and 0.16 ± 0.30 at corresponding postoperative time points (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g005" target="_blank">Fig 5</a>).…”